EAGAN, Minn., May 02, 2023 (GLOBE NEWSWIRE) — Predictive Oncology Inc. POAI, a science-driven company that leverages its proprietary artificial intelligence and machine learning, extensive biorepository of tumor specimens, Clinical Laboratory Improvement Amendments (CLIA) lab and Good Manufacturing Practices (GMP) facility to accelerate oncology drug discovery and to enable drug development announced the appointment of Veena Rao, Ph.D., MBA, with experience in healthcare commercial and business development, to its board of directors. dr Rao is currently Chief Business Officer of Portal Instruments, where she leads the identification, evaluation and negotiation of partnership opportunities for Portal and leads a cross-functional team of academics and business people to guide the company’s short- and long-term commercial strategy. dr Rao will replace David Smith, who is stepping down but will remain an advisor to the Board of Directors and assume responsibilities as the company’s legal counsel.

“We are very pleased to have someone of Veena’s experience and background join a world-class Board of Directors,” said Raymond F. Vennare, Chief Executive Officer of Predictive Oncology. “As our declining momentum continues to accelerate, we will draw heavily on Veena’s extensive experience, and I look forward to her contributions.”

“I joined the board of Predictive Oncology because I see the significant and rapidly growing role that AI and machine learning can play in drug discovery,” noted Dr. rao “Predictive’s PEDAL AI platform, together with its proprietary biobank, CLIA laboratory and formulation services, provides the company with a unique portfolio of assets and capabilities that I believe make it the ‘partner of choice’ for both commercial drug developers and drug developers for research organizations looking to de-risk their drug discovery and development programs. I look forward to working with Raymond and my fellow board members to lead this…